Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Briacell Therapeutics Corp BCTX


Primary Symbol: T.BCT Alternate Symbol(s):  BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted... see more

TSX:BCT - Post Discussion

Briacell Therapeutics Corp > price pivot is around $1,20
View:
Post by loopsbutterfly on Oct 28, 2024 1:00pm

price pivot is around $1,20

a move to $1,60 is very likely...stay tune

just watch and learn

gracias     grinnnnn....
Comment by loopsbutterfly on Oct 30, 2024 1:24pm
I have been wrong...at least in the short term last trade $1,08
Comment by wallpaper2 on Nov 17, 2024 4:40am
A mive to 1.60.  Watch and learn wtf. Who is this cliwn?
Comment by drongodragon on Nov 21, 2024 4:40pm
Don't know who the clown is but I am watching with today's move. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities